The immune reprogramming and overcoming immune tolerance during tumor growth require multi-targeting aspects of the immune system using combinations that aim to stimulate DCs, trigger signaling via T cell co-stimulatory receptors (e.g., OX40, also known as CD134) and inhibit signaling via T cell co-inhibitory molecules (e.g., PD1). This evidence concerns the gene TNFRSF4 and neoplasm.